SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01581827

Acronym

SHF-L

Enrollment

3000

Registered

2012-04-20

Start date

2009-01-31

Completion date

2017-12-31

Last updated

2018-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart Failure, BNP, NT-proBNP

Brief summary

Heart failure (when the heart does not pump as well as it used to) is a medical condition which reduces the quality of life for the sufferers. Approximately 10% of people in western societies aged over 75 develop heart failure. There has been a shift towards prevention of this disease and it is hoped that BNP (brain natriuretic peptides) and NT-proBNP (N-terminal proBNP) will prove to be useful indicators of those at greatest risk. The current study therefore plans to follow up the 3500 participants at risk of heart failure from the original SCREEN-HF study. Participants who are willing to participate will be contacted annually. They will undergo a short physical exam, will be asked to complete a Quality of Life questionnaire and will have a blood sample taken. At the end of the study participants will also have an ECG and an echocardiogram.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Consented and enrolled in the SCREEN-HF study and who agreed to further contact 2. Age ≥ 60 years 3. Subjects at high-risk of subsequent development of heart failure; comprising at least one of: * Prior myocardial infarction (MI) without known left ventricular (LV) dysfunction * Current active ischaemic heart disease * Prior Cerebrovascular Accident (CVA) * Known valvular heart disease without known LV dysfunction * Atrial fibrillation * Treated hypertension, of at least 2 years duration * Treated Diabetes mellitus, of at least 2 years duration * Chronic renal impairment (eGFR \< 60 ml/min)

Exclusion criteria

1. Known systolic or diastolic heart failure 2. LV systolic or diastolic dysfunction on echocardiography or other objective imaging modality (if known).

Design outcomes

Primary

Measure	Time frame
Change in NT-proBNP	baseline and 5 years
Change in echocardiogram	baseline and 5 years

Secondary

Measure	Time frame
incidence of new heart failure	baseline and 5 years

Countries

Australia

Outcome results